Cancer-associated Thrombosis
Conditions
Brief summary
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.
Detailed description
CAN-CATCH study is a prospective cohort study to develop a risk assessment model for VTE recurrence and clinically relevant bleeding in patients with CAT. The study is anticipated to recruit for a period of 2 years with a 3-year completion timeline. The primary objective of this study is to prospectively develop a RAM that accurately identifies anticoagulated CAT patients at low- and high-risk of CAT recurrence and clinically relevant bleeding within 6 months following the CAT diagnosis. The secondary objective is to create a biobank of plasma and DNA samples at the time of CAT diagnosis, linked to the annotated dataset for future translational biomarker research in cancer genetics and hemostasis. At approved sites, participants will donate 4x4.5 mL 3.2% citrate tubes and 3x10 mL ethylenediaminetetraacetic (EDTA) tubes for blood banking. In addition to the initial enrollment visit, participants that are enrolled will have a follow up at day 90 ± 14 days (3 months) and at day 180 ± 14 days (6 months) from randomization. Post enrollment follow-up visits will include assessment and documentation of any major and clinically relevant non-major bleeding (CRNMB), investigations for VTE, change in cancer treatment regimen, VTE risk factors, bleeding risk factors and death. Participants who experience an outcome event should continue to be followed
Interventions
None listed
Sponsors
Canadian Institutes of Health Research (CIHR)
Ottawa Hospital Research Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types * Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing. * Estimated life expectancy \> 6 months * Willingness to give an informed consent * Age ≥ 18 years
Exclusion criteria
* Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis) * Superficial vein thrombosis * Refusal of informed consent \> 72 hrs of anticoagulants * Age \< 18 years old
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrent VTE | 6 months | The primary outcome of the study will include objectively confirmed recurrent VTE (distal and/or proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and/or splanchnic vein thrombosis and/or cerebral venous sinus thrombosis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall mortality | 6 months | Post-enrollment follow-up visits will include documentation of death if occuring at any time during the 6 month follow up period |
| Clinically relevant bleeding | 6 months | Post-enrollment follow-up visits will include assessment and documentation of any major and CRNMB and bleeding risk factors at any time during the 6 month follow up period. |
Countries
Canada
Contacts
Primary ContactKristina Vrotniakaite-Bajerciene, MD
Outcome results
None listed